1-20 of 24
Michael A. Caligiuri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy

Yoshihiro Otani, Ji Young Yoo, Cole T. Lewis, Samantha Chao, Jessica Swanner, Toshihiko Shimizu, Jin Muk Kang, Sara A. Murphy, Kimberly Rivera-Caraballo, Bangxing Hong, Joseph C. Glorioso, Hiroshi Nakashima, Sean E. Lawler, Yeshavanth Banasavadi-Siddegowda, John D. Heiss, Yuanqing Yan, Guangsheng Pei, Michael A. Caligiuri, Zhongming Zhao, E. Antonio Chiocca, Jianhua Yu, Balveen Kaur
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1460–1473.
https://doi.org/10.1158/1078-0432.CCR-21-2347
Published: 01 April 2022
View article titled, NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
Open the PDF for NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

Lei Tian, Bo Xu, Kun-Yu Teng, Mihae Song, Zheng Zhu, Yuqing Chen, Jing Wang, Jianying Zhang, Mingye Feng, Balveen Kaur, Lorna Rodriguez, Michael A. Caligiuri, Jianhua Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 201–214.
https://doi.org/10.1158/1078-0432.CCR-21-1248
Published: 05 January 2022
View article titled, Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Open the PDF for Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition

Yoshihiro Otani, Ji Young Yoo, Samantha Chao, Joseph Liu, Alena Cristina Jaime-Ramirez, Tae Jin Lee, Brian Hurwitz, Yuanqing Yan, Hongsheng Dai, Joseph C. Glorioso, Michael A. Caligiuri, Jianhua Yu, Balveen Kaur
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2381–2392.
https://doi.org/10.1158/1078-0432.CCR-19-3420
Published: 15 May 2020
View article titled, Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition
Open the PDF for Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

Elizabeth L. McMichael, Brooke Benner, Lakhvir S. Atwal, Nicholas B. Courtney, Xiaokui Mo, Melanie E. Davis, Amanda R. Campbell, Megan C. Duggan, Kallan Williams, Kyle Martin, Kala Levine, Gonzalo N. Olaverria Salavaggione, Tiffany Noel, Akaansha Ganju, Sarvani Uppati, Bonnie Paul, Thomas Olencki, Theodoros N. Teknos, Panos Savvides, Susheela Tridandapani, John C. Byrd, Michael A. Caligiuri, Stephen V. Liu, William E. Carson, III
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4955–4965.
https://doi.org/10.1158/1078-0432.CCR-18-2108
Published: 15 August 2019
View article titled, A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Open the PDF for A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells

Yufeng Wang, Yibo Zhang, Tiffany Hughes, Jianying Zhang, Michael A. Caligiuri, Don M. Benson, Jianhua Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 4006–4017.
https://doi.org/10.1158/1078-0432.CCR-17-3117
Published: 14 August 2018
View article titled, Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <em>Ex Vivo</em>–Expanded Autologous NK Cells
Open the PDF for Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <em>Ex Vivo</em>–Expanded Autologous NK Cells in another window
Includes: Supplementary data
Journal Articles

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone

James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Ludmila K. Martin, Mark Lustberg, John Patton, Marisa Martin, Ying Huang, Gerard Nuovo, Fengting Yan, Robert Cavaliere, Joyce Fingeroth, Shannon C. Kenney, Richard F. Ambinder, Gerard Lozanski, Pierluigi Porcu, Michael A. Caligiuri, Robert A. Baiocchi
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3273–3281.
https://doi.org/10.1158/1078-0432.CCR-17-2685
Published: 15 July 2018
View article titled, Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
Open the PDF for Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone in another window
Includes: Supplementary data
Journal Articles

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy

Chelsea Bolyard, W. Hans Meisen, Yeshavanth Banasavadi-Siddegowda, Jayson Hardcastle, Ji Young Yoo, Eric S. Wohleb, Jeffrey Wojton, Jun-Ge Yu, Samuel Dubin, Maninder Khosla, Bo Xu, Jonathan Smith, Christopher Alvarez-Breckenridge, Pete Pow-anpongkul, Flavia Pichiorri, Jianying Zhang, Matthew Old, Dan Zhu, Erwin G. Van Meir, Jonathan P. Godbout, Michael A. Caligiuri, Jianhua Yu, Balveen Kaur
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (7): 1809–1819.
https://doi.org/10.1158/1078-0432.CCR-16-1818
Published: 02 April 2017
View article titled, BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Open the PDF for BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy in another window
Includes: Supplementary data
Journal Articles

Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy

Ji Young Yoo, Alena Cristina Jaime-Ramirez, Chelsea Bolyard, Hongsheng Dai, Tejaswini Nallanagulagari, Jeffrey Wojton, Brian S. Hurwitz, Theresa Relation, Tae Jin Lee, Michael T. Lotze, Jun-Ge Yu, Jianying Zhang, Carlo M. Croce, Jianhua Yu, Michael A. Caligiuri, Matthew Old, Balveen Kaur
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5265–5276.
https://doi.org/10.1158/1078-0432.CCR-16-1003
Published: 31 October 2016
View article titled, Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
Open the PDF for Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

Don M. Benson, Jr, Adam D. Cohen, Sundar Jagannath, Nikhil C. Munshi, Gary Spitzer, Craig C. Hofmeister, Yvonne A. Efebera, Pascale Andre, Robert Zerbib, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4055–4061.
https://doi.org/10.1158/1078-0432.CCR-15-0304
Published: 14 September 2015
View article titled, A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma in another window
Journal Articles

Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects

Ji Young Yoo, Brian S. Hurwitz, Chelsea Bolyard, Jun-Ge Yu, Jianying Zhang, Karuppaiyah Selvendiran, Kellie S. Rath, Shun He, Zachary Bailey, David Eaves, Timothy P. Cripe, Deborah S. Parris, Michael A. Caligiuri, Jianhua Yu, Matthew Old, Balveen Kaur
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3787–3798.
https://doi.org/10.1158/1078-0432.CCR-14-0553
Published: 14 July 2014
View article titled, Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
Open the PDF for Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer

Anjali Mishra, Laura Sullivan, Michael A. Caligiuri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (8): 2044–2050.
https://doi.org/10.1158/1078-0432.CCR-12-3603
Published: 15 April 2014
View article titled, Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Open the PDF for Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer in another window
Journal Articles

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

Xiaomeng Huang, Sebastian Schwind, Bo Yu, Ramasamy Santhanam, Hongyan Wang, Pia Hoellerbauer, Alice Mims, Rebecca Klisovic, Alison R. Walker, Kenneth K. Chan, William Blum, Danilo Perrotti, John C. Byrd, Clara D. Bloomfield, Michael A. Caligiuri, Robert J. Lee, Ramiro Garzon, Natarajan Muthusamy, Ly James Lee, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2355–2367.
https://doi.org/10.1158/1078-0432.CCR-12-3191
Published: 30 April 2013
View article titled, Targeted Delivery of <em>microRNA-29b</em> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Open the PDF for Targeted Delivery of <em>microRNA-29b</em> by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents

Rosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, Bo Yu, Yan Jin, Gerard Lozanski, Carolyn Cheney, Nyla Heerema, David Jarjoura, Amy Lehman, L. James Lee, Guido Marcucci, Robert J. Lee, Michael A. Caligiuri, Natarajan Muthusamy, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 569–578.
https://doi.org/10.1158/1078-0432.CCR-07-1006
Published: 25 January 2008
View article titled, A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Open the PDF for A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents in another window
Journal Articles

Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

Syed-Rehan A. Hussain, Carolyn M. Cheney, Amy J. Johnson, Thomas S. Lin, Michael R. Grever, Michael A. Caligiuri, David M. Lucas, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2144–2150.
https://doi.org/10.1158/1078-0432.CCR-06-2294
Published: 02 April 2007
View article titled, Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity
Open the PDF for Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity in another window
Journal Articles

A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

Khuda D. Khan, Christos Emmanouilides, Don M. Benson, Jr., Deborah Hurst, Pablo Garcia, Glenn Michelson, Sandra Milan, Amy K. Ferketich, Lawrence Piro, John P. Leonard, Pierluigi Porcu, Charles F. Eisenbeis, Amy L. Banks, Lei Chen, John C. Byrd, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7046–7053.
https://doi.org/10.1158/1078-0432.CCR-06-1571
Published: 04 December 2006
View article titled, A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
Open the PDF for A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma in another window
Journal Articles

A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer

Manisha H. Shah, Aharon G. Freud, Don M. Benson, Jr., Amy K. Ferkitich, Bruce J. Dezube, Zale P. Bernstein, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3993–3996.
https://doi.org/10.1158/1078-0432.CCR-06-0268
Published: 03 July 2006
View article titled, A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer
Open the PDF for A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer in another window
Journal Articles

Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35

Flavia Pichiorri, Francesco Trapasso, Tiziana Palumbo, Rami I. Aqeilan, Alessandra Drusco, Bradley W. Blaser, Dimitrios Iliopoulos, Michael A. Caligiuri, Kay Huebner, Carlo M. Croce
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3494–3501.
https://doi.org/10.1158/1078-0432.CCR-05-2581
Published: 01 June 2006
View article titled, Preclinical Assessment of <em>FHIT</em> Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35
Open the PDF for Preclinical Assessment of <em>FHIT</em> Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35 in another window
Journal Articles

Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions

Clara D. Bloomfield, Krzysztof Mrózek, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3564s–3571s.
https://doi.org/10.1158/1078-0432.CCR-06-9002
Published: 01 June 2006
View article titled, Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions
Open the PDF for Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions in another window
Journal Articles

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

Guowei Dai, Kenneth K. Chan, Shujun Liu, Dale Hoyt, Susan Whitman, Marko Klisovic, TianSheng Shen, Michael A. Caligiuri, John Byrd, Michael Grever, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 2998–3008.
https://doi.org/10.1158/1078-0432.CCR-04-1505
Published: 18 April 2005
View article titled, Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia
Open the PDF for Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia in another window
Journal Articles

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study

Charles F. Eisenbeis, Andrew Grainger, Beth Fischer, Robert A. Baiocchi, Lester Carrodeguas, Sameek Roychowdhury, Lei Chen, Amy L. Banks, Thomas Davis, Donn Young, Nicole Kelbick, Julie Stephens, John C. Byrd, Michael R. Grever, Michael A. Caligiuri, Pierluigi Porcu
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6101–6110.
https://doi.org/10.1158/1078-0432.CCR-04-0525
Published: 24 September 2004
View article titled, Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: <subtitle>A Preclinical and Phase I Study</subtitle>
Open the PDF for Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: <subtitle>A Preclinical and Phase I Study</subtitle> in another window